Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin for epithelial dysplasia in oral potentially malignant disorders
IRCT20260714070188N1Phase 2Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of metformin in oral premalignancies, leukoplakia and oral lichen planus (OLP), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoint: Histopathological changes in the degree of epithelial dysplasia. Started Aug 2026; status: completed.
02
Drugs
metformin
03
Conditions
oral premalignanciesleukoplakiaoral lichen planus (OLP)
Beyond the preview
Go deeper on IRCT20260714070188N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260714070188N1.